End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.047 NZD | -4.08% | -6.00% | -60.83% |
05-07 | Rua Bioscience Extends Distribution Agreement with Germany's Nimbus Health | MT |
05-07 | Rua Bioscience Limited Extends Agreement with Nimbus Health in Germany | CI |
Business Summary
Sales per Business
NZD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical Manufacturing
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +1,376.41% |
Sales per region
NZD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
New Zealand
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | +1,376.41% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Paul Naske
CEO | Chief Executive Officer | - | 31/01/19 |
Manu Caddie
FOU | Founder | - | 31/12/15 |
Liam Walker
DFI | Director of Finance/CFO | - | - |
Anna Stove
CHM | Chairman | - | 30/04/19 |
Jessika Nowak
CTO | Chief Tech/Sci/R&D Officer | - | 28/02/19 |
Emma McIldowie
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Anthony Barclay
BRD | Director/Board Member | - | 30/04/23 |
Anna Stove
CHM | Chairman | - | 30/04/19 |
Director/Board Member | - | 31/07/22 | |
Panapa Ehau
FOU | Founder | - | 31/12/15 |
Paul Naske
CEO | Chief Executive Officer | - | 31/01/19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 158,136,265 | 83,728,337 ( 52.95 %) | 0 | 52.95 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
-60.83% | 4.59M | |
+29.76% | 5.69B | |
-32.34% | 3.53B | |
-2.23% | 3.06B | |
-25.26% | 2.62B | |
-10.88% | 2.29B | |
+40.09% | 1.86B | |
+40.90% | 1.43B | |
-15.16% | 1.41B | |
+42.86% | 1.4B |
- Stock Market
- Equities
- RUA Stock
- Company Rua Bioscience Limited